These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 31080102)

  • 1. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
    Nascimento B; Miranda EP; Jenkins LC; Benfante N; Schofield EA; Mulhall JP
    J Sex Med; 2019 Jun; 16(6):872-879. PubMed ID: 31080102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer.
    Planas J; Celma A; Placer J; Cuadras M; Regis L; Gasanz C; Trilla E; Salvador C; Lorente D; Morote J
    Scand J Urol; 2016 Dec; 50(6):425-428. PubMed ID: 27628623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer.
    Nam W; Choi SY; Yoo SJ; Ryu J; Lee J; Kyung YS; Han JH; You D; Jeong IG; Hong JH; Ahn H; Kim CS
    Investig Clin Urol; 2018 Jan; 59(1):18-24. PubMed ID: 29333510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of testosterone-guided androgen deprivation therapy in management of prostate cancer.
    Niraula S; Templeton AJ; Vera-Badillo FE; Joshua AM; Sridhar SS; Cheung PW; Yip PM; Dodd A; Nugent Z; Tannock IF
    Prostate; 2016 Feb; 76(2):235-42. PubMed ID: 26768279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of testosterone recovery in clinically localized prostate cancer patients treated with radical prostatectomy and subsequent short-term adjuvant androgen deprivation therapy.
    Dai B; Qu YY; Kong YY; Ye DW; Yao XD; Zhang SL; Zhang HL; Yang WY
    Asian J Androl; 2013 Jul; 15(4):466-70. PubMed ID: 23708460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy.
    Takei A; Sakamoto S; Wakai K; Tamura T; Imamura Y; Xu M; Maimaiti M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
    Int J Urol; 2018 Apr; 25(4):352-358. PubMed ID: 29323427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy.
    Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
    Int J Biol Markers; 2005; 20(2):119-22. PubMed ID: 16011042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased testosterone recovery after androgen deprivation therapy for prostate cancer.
    Long ME; Vitale AM; Mott SL; Tracy C; Garje R; Zakharia Y; Brown JA
    Can J Urol; 2021 Aug; 28(4):10738-10742. PubMed ID: 34378507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
    Bong GW; Clarke HS; Hancock WC; Keane TE
    Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients.
    Wang Y; Dai B; Ye DW
    Asian J Androl; 2017; 19(2):178-183. PubMed ID: 26975487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Relationship between Hot Flashes and Testosterone Recovery after 12 Months of Androgen Suppression for Men with Localised Prostate Cancer in the ASCENDE-RT Trial.
    Dosani M; Morris WJ; Tyldesley S; Pickles T
    Clin Oncol (R Coll Radiol); 2017 Oct; 29(10):696-701. PubMed ID: 28712786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extraction of Treatment Information From Electronic Health Records and Evaluation of Testosterone Recovery in Patients With Prostate Cancer.
    Guin S; Jun T; Patel VG; Ayers KL; Deitz M; Cai Y; Zhou X; Tsao CK; Oh WK; Chen R; Liaw BC
    JCO Clin Cancer Inform; 2022 Jun; 6():e2200010. PubMed ID: 35696627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer.
    Spratt DE; George DJ; Shore ND; Cookson MS; Saltzstein DR; Tutrone R; Bossi A; Brown BA; Lu S; Fallick M; Hanson S; Tombal BF
    JAMA Oncol; 2024 May; 10(5):594-602. PubMed ID: 38451492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial.
    Zapatero A; Álvarez A; Guerrero A; Maldonado X; González San Segundo C; Cabeza MA; Martín de Vidales C; Solé JM; Pedro Olivé A; Casas F; Boladeras A; Vázquez de la Torre ML; Vara S; Calvo FA
    Radiother Oncol; 2021 Jul; 160():115-119. PubMed ID: 33964325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of androgen deprivation therapy in prostate cancer patients.
    Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
    Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy.
    Yamamoto S; Sakamoto S; Minhui X; Tamura T; Otsuka K; Sato K; Maimaiti M; Kamada S; Takei A; Fuse M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
    Clin Genitourin Cancer; 2017 Dec; 15(6):e1107-e1115. PubMed ID: 28882738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rise in serum folate after androgen deprivation associated with worse prostate cancer-specific survival.
    Liss MA; Ashcraft K; Satsangi A; Bacich D
    Urol Oncol; 2020 Aug; 38(8):682.e21-682.e27. PubMed ID: 32444177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Nomogram for Testosterone Recovery After Combined Androgen Deprivation and Radiation Therapy for Prostate Cancer.
    Spiegel DY; Hong JC; Oyekunle T; Waters L; Lee WR; Salama JK; Koontz BF
    Int J Radiat Oncol Biol Phys; 2019 Mar; 103(4):834-842. PubMed ID: 30419308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cessation of Primary Androgen Deprivation Therapy for Men With Localized Prostate Cancer.
    Fujimoto N; Kubo T; Tomisaki I
    Clin Genitourin Cancer; 2015 Aug; 13(4):359-363. PubMed ID: 25907231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.